Cargando…

A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases

Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Hideto, Raut, Bibek, Chen, Li-Jiun, Nagai, Nobuhiro, Abe, Toshiaki, Kaji, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231335/
https://www.ncbi.nlm.nih.gov/pubmed/32326233
http://dx.doi.org/10.3390/mi11040436
_version_ 1783535167702302720
author Kojima, Hideto
Raut, Bibek
Chen, Li-Jiun
Nagai, Nobuhiro
Abe, Toshiaki
Kaji, Hirokazu
author_facet Kojima, Hideto
Raut, Bibek
Chen, Li-Jiun
Nagai, Nobuhiro
Abe, Toshiaki
Kaji, Hirokazu
author_sort Kojima, Hideto
collection PubMed
description Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epithelial (ARPE-19) cells (cultured on collagen coated polystyrene (PS) sheets) enclosed inside a 3D printed semi-porous capsule. The capsule was 3D printed with two photo curable polymers: triethylene glycol dimethacrylate (TEGDM) and polyethylene glycol dimethylacrylate (PEGDM). The capsule’s semi-porous membrane (PEGDM) could serve three functions: protecting the cells from body’s immune system by limiting diffusion (5.97 ± 0.11%) of large molecules like immunoglobin G (IgG)(150 kDa); helping the cells to survive inside the capsule by allowing diffusion (43.20 ± 2.16%) of small molecules (40 kDa) like oxygen and necessary nutrients; and helping in the treatment of RDD by allowing diffusion of cell-secreted BDNF to the outside environment. In vitro results showed a continuous BDNF secretion from the device for at least 16 days, demonstrating future potential of the cell-encapsulation device for the treatment of RDD in a minimally invasive and self-sustainable way through a periocular transplant.
format Online
Article
Text
id pubmed-7231335
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72313352020-05-22 A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases Kojima, Hideto Raut, Bibek Chen, Li-Jiun Nagai, Nobuhiro Abe, Toshiaki Kaji, Hirokazu Micromachines (Basel) Article Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epithelial (ARPE-19) cells (cultured on collagen coated polystyrene (PS) sheets) enclosed inside a 3D printed semi-porous capsule. The capsule was 3D printed with two photo curable polymers: triethylene glycol dimethacrylate (TEGDM) and polyethylene glycol dimethylacrylate (PEGDM). The capsule’s semi-porous membrane (PEGDM) could serve three functions: protecting the cells from body’s immune system by limiting diffusion (5.97 ± 0.11%) of large molecules like immunoglobin G (IgG)(150 kDa); helping the cells to survive inside the capsule by allowing diffusion (43.20 ± 2.16%) of small molecules (40 kDa) like oxygen and necessary nutrients; and helping in the treatment of RDD by allowing diffusion of cell-secreted BDNF to the outside environment. In vitro results showed a continuous BDNF secretion from the device for at least 16 days, demonstrating future potential of the cell-encapsulation device for the treatment of RDD in a minimally invasive and self-sustainable way through a periocular transplant. MDPI 2020-04-21 /pmc/articles/PMC7231335/ /pubmed/32326233 http://dx.doi.org/10.3390/mi11040436 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kojima, Hideto
Raut, Bibek
Chen, Li-Jiun
Nagai, Nobuhiro
Abe, Toshiaki
Kaji, Hirokazu
A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
title A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
title_full A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
title_fullStr A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
title_full_unstemmed A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
title_short A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
title_sort 3d printed self-sustainable cell-encapsulation drug delivery device for periocular transplant-based treatment of retinal degenerative diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231335/
https://www.ncbi.nlm.nih.gov/pubmed/32326233
http://dx.doi.org/10.3390/mi11040436
work_keys_str_mv AT kojimahideto a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT rautbibek a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT chenlijiun a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT nagainobuhiro a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT abetoshiaki a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT kajihirokazu a3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT kojimahideto 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT rautbibek 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT chenlijiun 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT nagainobuhiro 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT abetoshiaki 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases
AT kajihirokazu 3dprintedselfsustainablecellencapsulationdrugdeliverydeviceforperioculartransplantbasedtreatmentofretinaldegenerativediseases